Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials
Rutherford, Sarah C. , Yin, Jun , Pederson, Levi , Burbano, Gabriela Perez , LaPlant, Betsy, Kenkre, Vaishalee P. , Hong, Fangxin , Blum, Kristie A. , Dockter, Travis , Martin, Peter , Grant, Barbara, Rosenbaum, Cara A. , Ujjani, Chaitra S. , Cheson, Bruce D. , Bartlett, Nancy L. , Friedberg, Jonathan W. , Mandrekar, Sumithra J. , Leonard, John P. , Perez Burbano, Gabriela, Hong, Fangxin , Blum, Kristie A , Dockter, Travis , Martin, Peter , Jung, Sin‐Ho , Rosenbaum, Cara , Barr, Paul M , Unger, Joseph M , Cheson, Bruce D , Bartlett, Nancy L , Kahl, Brad S , Mandrekar, Sumithra J , Shadman, Mazyar , Li, Hongli , LeBlanc, Michael , Barr, Paul M. , Unger, Joseph M. , Kahl, Brad S.

Mayo Clinic

Journal of Clinical Oncology | July 5, 2022 | Volume: 41 | Issue: 2 | Pages: 336-342

10.1200/jco.21.02301 | PMID 35787017 Get It

PURPOSE Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in assessing response or predict progression-free survival (PFS) or overall survival (OS) outcomes in follicular lymphoma (FL) subjects in a large, multicenter, multitrial cohort. METHODS Data were pooled from seven trials of 580 subjects with previously untreated FL through Alliance for Clinical Trials in Oncology (Alliance) and SWOG Cancer Research Network (SWOG) completing enrollment from 2008 to 2016. RESULTS Only 5/580 (0.9%) had positive baseline BMB, CR on imaging, and subsequent positive BMB ( P < .0001). Therefore, BMB were irrelevant to response in 99% of subjects. A sensitivity analysis of 385 FL subjects treated on an Eastern Cooperative Oncology Group study was included. In the Eastern Cooperative Oncology Group cohort, 5/385 (1.3%) had BMB that affected response assessment. Since some subjects do not undergo confirmatory BMB, we performed a landmark survival analysis from first radiologic CR with data from 580 subjects from Alliance and SWOG. Of subjects with CR on imaging (n = 187), PFS and OS were not significantly different among those with negative BMB to confirm CR (n = 47) versus those without repeat BMB (n = 140; PFS: adjusted hazard ratio, 1.10, 95% CI, 0.62 to 1.94, log-rank P = .686; OS: hazard ratio, 0.59, 95% CI, 0.23 to 1.53, log-rank P = .276). CONCLUSION We conclude that BMB add little value to response assessment in subjects with FL treated on clinical trials and we recommend eliminating BMB from clinical trial requirements. BMB should also be removed from diagnostic guidelines for FL except in scenarios in which it may change management including confirmation of limited stage and assessment of cytopenias. This would reduce cost, patient discomfort, resource utilization, and potentially remove a barrier to trial enrollment.
Acute pain pathways: protocol for a prospective cohort study
Jeffery, Molly M. , Ahadpour, Mitra , Allen, Summer V. , Araojo, Richardae , Bellolio, Fernanda , Chang, Nancy, Ciaccio, Laura , Emanuel, Lindsay, Fillmore, Jonathan J., Gilbert, Gregg H. , Koussis, Patricia, Lee, Christine , Lipkind, Heather S. , Mallama, Celeste A. , Meyer, Tamra E. , Moncur, Megan, Nuckols, Teryl K. , Pacanowski, Michael , Page, David B. , Papadopoulos, Elektra J., Ritchie, Jessica , Shah, Nilay D. , Soukup, Mat, Clair, Christopher St. , Tamang, Stephen, Torbati, Sam , Wallace, Douglas W. , Zhao, Yueqin, Heckmann, Rebekah, Jeffery, Molly Moore , Allen, Summer , Fillmore, Jonathan, Bellolio, M Fernanda , Fillmore, Jonathan, Lee, Christine H. , Ross, Joseph S.

Mayo Clinic

BMJ Open | July 5, 2022 | Volume: 12 | Issue: 7 | Pages: e058782

10.1136/bmjopen-2021-058782 | PMID 35790333 Get It

Introduction Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. An essential element to developing evidence-based guidelines is a better understanding of pain management and pain control among individuals experiencing acute pain for various common diagnoses. Methods and analysis This multicentre prospective observational study will recruit 1550 opioid-naïve participants with acute pain seen in diverse clinical settings including primary/urgent care, emergency departments and dental clinics. Participants will be followed for 6 months with the aid of a patient-centred health data aggregating platform that consolidates data from study questionnaires, electronic health record data on healthcare services received, prescription fill data from pharmacies, and activity and sleep data from a Fitbit activity tracker. Participants will be enrolled to represent diverse races and ethnicities and pain conditions, as well as geographical diversity. Data analysis will focus on assessing patients’ patterns of pain and opioid analgesic use, along with other pain treatments; associations between patient and condition characteristics and patient-centred outcomes including resolution of pain, satisfaction with care and long-term use of opioid analgesics; and descriptive analyses of patient management of leftover opioids. Ethics and dissemination This study has received approval from IRBs at each site. Results will be made available to participants, funders, the research community and the public. Trial registration number NCT04509115 .
Emergency medicine physician supervision and mortality among patients receiving care from non-physician clinicians in a task-sharing model of emergency care in rural Uganda: a retrospective analysis of a single-centre training programme
Rice, Brian , Pickering, Ashley , Laurence, Colleen , Kizito, Prisca Mary , Leff, Rebecca , Kisingiri, Steven Jonathan, Ndyamwijuka, Charles, Nakato, Serena, Adriko, Lema Felix, Bisanzo, Mark

Mayo Clinic

BMJ Open | June 29, 2022 | Volume: 12 | Issue: 6 | Pages: e059859

10.1136/bmjopen-2021-059859 | PMID 35768107 Get It

Objectives To assess the association between emergency medicine physician supervision and 3-day mortality for patients receiving care from non-physician clinicians in a task-sharing model of emergency care in rural Uganda. Design Retrospective cohort analysis with multivariable logistic regression. Setting Single rural Ugandan emergency unit. Participants All patients presenting for care from 2009 to 2019. Interventions Three cohorts of patients receiving care from non-physician clinicians had three different levels of physician supervision: ‘Direct Supervision’ (2009–2010) emergency medicine physicians directly supervised all care; ‘Indirect Supervision’ (2010–2015) emergency medicine physicians were consulted as needed; ‘Independent Care’ (2015–2019) no emergency medicine physician supervision. Primary outcome measure Three-day mortality. Results 38 033 ED visits met inclusion criteria. Overall mortality decreased significantly across supervision cohorts (‘Direct’ 3.8%, ‘Indirect’ 3.3%, ‘Independent’ 2.6%, p<0.001), but so too did the rates of patients who presented with ≥3 abnormal vitals (‘Direct’ 32%, ‘Indirect’ 19%, ‘Independent’ 13%, p<0.001). After controlling for vital sign abnormalities, ‘Direct’ and ‘Indirect’ supervision were both significantly associated with reduced OR for mortality (‘Direct’: 0.57 (0.37 to 0.90), ‘Indirect’: 0.71 (0.55 to 0.92)) when compared with ‘Independent Care’. Sensitivity analysis showed that this mortality benefit was significant for the minority of patients (17.2%) with ≥3 abnormal vitals (‘Direct’: 0.44 (0.22 to 0.85), ‘Indirect’: 0.60 (0.41 to 0.88)), but not for the majority (82.8%) with two or fewer abnormal vitals (‘Direct’: 0.81 (0.44 to 1.49), ‘Indirect’: 0.82 (0.58 to 1.16)). Conclusions Emergency medicine physician supervision of emergency care non-physician clinicians is independently associated with reduced overall mortality. This benefit appears restricted to the highest risk patients based on abnormal vitals. With over 80% of patients having equivalent mortality outcomes with independent non-physician clinician emergency care, a synergistic model providing variable levels of emergency medicine physician supervision or care based on patient acuity could safely address staffing shortages.
Factors involved in applicant interview selection and ranking for chronic pain medicine fellowship
Francio, Vinicius Tieppo , Gill, Benjamin , Hagedorn, Jonathan M. , Pagan‐Rosado, Robert , Pritzlaff, Scott , Furnish, Timothy , Kohan, Lynn , Sayed, Dawood , Tieppo Francio, Vinicius , Hagedorn, Jonathan M

Mayo Clinic

Regional Anesthesia & Pain Medicine | June 27, 2022 | Volume: 47 | Issue: 10 | Pages: 592-597

10.1136/rapm-2022-103538 | PMID 35760514 Get It

Introduction Applicants to chronic pain medicine fellowship programs often express confusion regarding the importance of various selection criteria. This study sought to elucidate program directors’ considerations in applicant selection for fellowship interviews and ranking and to correlate these criteria with match statistics to provide a guide for prospective candidates. Methods An electronic survey was sent to all Accreditation Council for Graduate Medical Education-accredited chronic pain fellowship directors. The importance of various applicant characteristics were evaluated and compared with recent match data. Results Fifty-seven program directors completed the survey. The most important factors involved in applicant interview selection were perceived commitment to the specialty, letters of recommendation from pain faculty, scholarly activities, and leadership experiences. Although completion of a pain rotation was valued highly, experience with procedures was of relatively low importance. There was no preference if rotations were completed within the responders’ department. Variability was noted when considering internal applicants or the applicant’s geographic location. When citing main factors in ranking applicants, interpersonal skills, interview impression and applicant’s fit within the institution were highly ranked by most responders. Discussion Assessment of an applicant’s commitment to chronic pain is challenging. Most responders prioritize the applicant’s commitment to chronic pain as a specialty, scholarly activity, participation in chronic pain rotations, pain-related conferences and letters of recommendation from pain faculty. Chronic pain medicine fellowship candidates should establish a progressive pattern of genuine interest and involvement within the specialty during residency training to optimize their fellowship match potential.
Preoperative hemoglobin A1c and perioperative blood glucose in patients with diabetes mellitus undergoing spinal cord stimulation surgery: A literature review of surgical site infection risk
Hagedorn, Jonathan M. , Bendel, Markus A. , Hoelzer, Bryan C. , Aiyer, Rohit , Caraway, David , Hagedorn, Jonathan M

Mayo Clinic

Pain Practice | June 24, 2022 | Volume: 23 | Issue: 1 | Pages: 83-93

10.1111/papr.13145 | PMID 35748888 Get It

Abstract Aims The aim of our study was to review the surgical literature regarding the relationship between hemoglobin A1c (HbA1c), diagnosis of diabetes mellitus (DM), and risk of postoperative surgical site infection (SSI). Methods A librarian‐assisted literature search was performed with two goals: (1) identify surgical publications related to SSI and HbA1c values, and (2) identify publications reporting infection risk with DM in spinal cord stimulation (SCS), intrathecal drug delivery systems (IDDS), and cardiovascular implantable electronic device (CIED) implantation surgeries. Published guidelines on perioperative management of DM are reviewed. Results We identified 30 studies reporting SSI and HbA1c values. The literature review indicated that for many surgical procedures, elevated HbA1c is not correlated to rate of SSI. We identified 16 studies reporting infection rates within DM cohorts following SCS, IDDS, and CIED implantation surgeries. The data reviewed did not indicate DM as an independent risk factor for SSI. Conclusion Preoperative HbA1c levels in patients with a history of DM is not a singularly sufficient tool to estimate risk of perioperative infection in SCS implantation surgery. Published guidelines on perioperative management of DM do not suggest a specific HbA1c above which surgery should be delayed; intentional perioperative glycemic control is recommended.
P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
Zinzani, P. L., Ansell, S. M., Bosch, F., Friedberg, Jonathan W. , Marolleau, Jean Pierre, Arcaini, L., Gopal, A. K., Grande, C., Merryman, R., Pinto, A., Smith, S. D., Wallace, D., Fagerberg, J., Magalhaes, J. G., Armand, P., Zinzani, Pier Luigi , Ansell, Stephen M., García‐Sánz, Ramón , Gopal, A., Pinto, A., Villasboas, José C. , Fagerberg, J., Magalhaes, J. Gamelas

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1005-1006

10.1097/01.hs9.0000847328.48663.29 Get It

Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis
Chang, Bryce Kalei , Day, Gregory S. , Graff‐Radford, Jonathan, Nguyen, Aivi T. , Toledano, Michel , Kremers, Walter K. , Petersen, Ronald C. , Chang, Bryce K , Day, Gregory S , Nguyen, Aivi T , Kremers, Walter K , Graff‐Radford, Jonathan , McKeon, Andrew , Flanagan, Eoin P. , Algeciras‐Schimnich, Alicia , Mielke, Michelle M. , Jones, David T. , Knopman, David S. , Li, Wentao

Mayo Clinic

European Journal of Neurology | June 23, 2022 | Volume: 29 | Issue: 10 | Pages: 2905-2912

10.1111/ene.15469 | PMID 35735602 Get It

AbstractBackground and purposeAutoimmune encephalitis (AE) is a potentially treatable cause of rapidly progressive dementia that may mimic Creutzfeldt–Jakob disease (CJD). Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers may discriminate CJD from AD, but utility in discriminating CJD and AE is unclear. This study compared AD CSF biomarkers in CJD and AE.MethodsPatients with probable or definite CJD and probable or definite AE who underwent Roche Elecsys AD CSF biomarker testing at Mayo Clinic from March 2020 through April 2021 were included. Total‐tau, phosphorylated181 tau and amyloid‐β42 levels were compared.ResultsOf 11 CJD cases, four were autopsy proven; the rest had positive real‐time quaking‐induced conversion testing. Disease‐associated autoantibodies were detected in 8/15 cases of AE: leucine‐rich glioma‐inactivated 1 and neuronal intermediate filaments (two cases each), and N‐methyl‐d‐aspartate receptor, contactin‐associated protein‐like 2, dipeptidyl‐peptidase‐like protein 6 and immunoglobulin‐like cell adhesion molecule IgLON family member 5. Total‐tau provided excellent discrimination between CJD and AE in a univariate model (odds ratio 1.46 per 100 pg/ml, 95% confidence interval 1.17–2.11, p < 0.05, c = 0.93). Total‐tau was elevated in 91% of CJD cases (median > 1300, range 236–>1300 pg/ml), of which 55% were above the limit of assay measurement (>1300 pg/ml). Total‐tau was elevated in 20% of AE cases (median 158, range 80–>1300 pg/ml).ConclusionTotal‐tau was greater in CJD than AE. Given that amyloid‐β42 and phosphorylated181 tau were comparable, the ratio differences were probably driven by elevated total‐tau in CJD. This study supports the role for AD biomarker testing in patients with rapidly progressive dementia.
S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
Ansell, S., Straus, David J. , Kim, W. S., Gallamini, Andrea , Ramchandren, Radhakrishnan , Friedberg, Jonathan W. , Eom, Hyeon‐Seok , Dong, C., Campana, Frank, Fenton, Keenan , Puhlmann, Markus , Hutchings, Martin , Connors, Joseph M. , Advani, Ranjana H. , Evens, Andrew M. , Smolewski, Piotr , Savage, Kerry J. , Bartlett, Nancy L. , Abramson, Jeremy S. , Radford, John

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 101-102

10.1097/01.hs9.0000843692.94815.d7 Get It

How to Infuse Joy in Your Practice: Our Journey to Sustainable Well-Being
Stonnington, Cynthia M. , Leighton, Jonathan A. , Jones, Keith , Jones, Keith W.

Mayo Clinic

American Journal of Gastroenterology | June 21, 2022 | Volume: 117 | Issue: 11 | Pages: 1723-1727

10.14309/ajg.0000000000001892 | PMID 35973170 Get It

Abstract A19: Aspirin use and ovarian cancer risk by lymphocyte infiltration
Hecht, Jonathan L. , Goode, Ellen L. , Sasamoto, Naoko , Barnard, Mollie , Trabert, Britton , Terry, Kathryn L. , Tworoger, Shelley S.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 18, 2022 | Volume: 29 | Issue: 9_Supplement | Pages: A19-A19

10.1158/1538-7755.modpop19-a19 Get It

Abstract Introduction: There is growing evidence to support a modest inverse association between daily aspirin use and ovarian cancer risk. We previously hypothesized that this association may differ by immune cell infiltration. In our prior study evaluating heterogeneity by tumor-associated macrophage (TAM) infiltration, aspirin use was associated with lower risk of ovarian cancer with high protumorigenic M2-type TAM infiltration, but not low M2-type TAM infiltration. The goal of the present study was to evaluate the hypothesis that the association between aspirin use and ovarian cancer risk also differs by infiltration with tumor-infiltrating lymphocytes (TILs). Methods: We included cases and matched controls from the Nurses’ Health Study (NHS), NHSII, and New England Case Control Study. Study participants self-reported aspirin use including regular use (≥1 x per week), duration of use, and number of tablets. A gynecologic pathologist (JLH), who was blinded to exposure status, reviewed hematoxylin and eosin stained tumor slides to quantify TILs for all cases (n=547). We used polytomous logistic regression, adjusted for ovarian cancer risk factors, to estimate odds ratios (OR) for aspirin use and ovarian cancer risk by TIL infiltration. Results: Overall, recent aspirin use was associated with lower risk of ovarian cancer compared with no regular aspirin use (OR=0.65, 95%CI=0.47-0.89). Recent aspirin use was associated with a lower risk of ovarian cancer exhibiting TIL infiltration (OR=0.38, 95%CI=0.26-0.56) but not with TIL-negative cancers (OR=1.00, 95%CI=0.71-1.41; p-heterogeneity &lt;0.001). We observed similar results for aspirin duration and tablets. For duration, comparing ≥10 years of aspirin use to &lt;1 year we observed a significantly lower risk of ovarian cancer with TILs (OR=0.47, 95%CI=0.41-0.71; p-trend=0.004), but a nonsignificant reduction for ovarian cancer without TILs (OR=0.86, 95%CI=0.59-1.26; p-trend=0.72; p-heterogeneity=0.03). Comparing ≥6 tablets to &lt;1 tablet per week, there was evidence of a lower risk of ovarian cancer with TILs (OR=0.47, 95%CI=0.30-0.75; p-trend=0.001) but not without TILs (OR=1.02, 95%CI=0.70-1.48; p-trend=0.84; p-heterogeneity=0.003). Conclusions: Our results suggest that prediagnosis aspirin use may be an important modulator of immune cell infiltration in ovarian tumors, supporting an immunogenic mechanism for aspirin in ovarian carcinogenesis. Further work is under way to evaluate nonaspirin nonsteroidal anti-inflammatory drugs, and to consider which subsets of TAMs and TILs may be driving heterogeneity in the associations between anti-inflammatory drugs and ovarian cancer risk. Citation Format: Mollie E. Barnard, Britton Trabert, Jonathan L. Hecht, Ellen L. Goode, Naoko Sasamoto, Kathryn L. Terry, Shelley S. Tworoger. Aspirin use and ovarian cancer risk by lymphocyte infiltration [abstract]. In: Proceedings of the AACR Special Conference on Modernizing Population Sciences in the Digital Age; 2019 Feb 19-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(9 Suppl):Abstract nr A19.